Search

The southern Tibetan Plateau (STP) is the region in which water vapor passes from South Asia into the Tibetan Plateau (TP). The accuracy of precipitable water vapor (PWV) modeling for this region depends strongly on the quality of the available estimates of water vapor advection and the parameterization of land evaporation models. While climate simulation is frequently improved by assimilating relevant satellite and reanalysis products, this requires an understanding of the accuracy of these products. In this study, PWV data from MODIS infrared and near-infrared measurements, AIRS Level-2 and Level-3, MERRA, ERA-Interim, JRA-55, and NCEP final reanalysis (NCEP-Final) are evaluated against ground-based GPS measurements at nine stations over the STP, which covers the summer monsoon season from 2007 to 2013. The MODIS infrared product is shown to underestimate water vapor levels by more than 20% (1.84 mm), while the MODIS near-infrared product overestimates them by over 40% (3.52 mm). The AIRS PWV product appears to be most useful for constructing high-resolution and high-quality PWV datasets over the TP; particularly the AIRS Level-2 product has a relatively low bias (0.48 mm) and RMSE (1.83 mm) and correlates strongly with the GPS measurements ( R = 0.90). The four reanalysis datasets exhibit similar performance in terms of their correlation coefficients ( R = 0.87-0.90), bias (0.72-1.49 mm), and RMSE (2.19-2.35 mm). The key finding is that all the reanalyses have positive biases along the PWV seasonal cycle, which is linked to the well-known wet bias over the TP of current climate models. [ABSTRACT FROM AUTHOR]

• An ultra-sensitive and visualized DNA sensing platform has been developed for better molecular diagnosis with CRISPR. • Make the common DNA sensing platform free of tedious DNA extraction and purification modules. • Dehydration operation of the fragile CRISPR reagent for its stable storage at room temperature. • Rapid and directly sensing of the popular Asia swine fever virus (ASFV) in unprocessed pig blood sample. Animal-borne diseases are often caused by zoonotic viruses that are hidden in their tissues or blood. Currently, for their diagnosis, the time-consuming sample pretreatment is inevitable which limit its field applicability and promotion. Herein, taking the recent popular African swine fever virus (ASFV) as an example, we proposed a new platform for their directly visualized analysis in the unprocessed blood sample by introducing in CRISPR tool coupled with loop-mediated isothermal amplification (LAMP). Besides, considering the instability of the CRISPR enzyme, in order to extend its shelf life, we also carried out the dehydration operation to make it free from the requirements of the low-temperature storage environment. This "sample to result" platform is capable of on-site detection and analysis which may also provide new ideas for diseases diagnosis in complex crude samples. [ABSTRACT FROM AUTHOR]

Background: Globally, there is increasing interest in the use of real-world data (RWD) and real-world evidence (RWE) to inform health technology assessment (HTA) and reimbursement decision-making. Using current practices and case studies shared by eleven health systems in Asia, a non-binding guidance that seeks to align practices for generating and using RWD/RWE for decision-making in Asia was developed by the REAL World Data I n A S ia for H E alth Technology Assessment in Reimbursement (REALISE) Working Group, addressing a current gap and needs among HTA users and generators., Methods: The guidance document was developed over two face-to-face workshops, in addition to an online survey, a face-to-face interview and pragmatic search of literature. The specific focus was on what, where and how to collect RWD/ RWE., Results: All 11 REALISE member jurisdictions participated in the online survey and the first in-person workshop, 10 participated in the second in-person workshop, and 8 participated in the in-depth face-to-face interviews. The guidance document was iteratively reviewed by all working group members and the International Advisory Panel. There was substantial variation in: ( a ) sources and types of RWD being used in HTA, and ( b ) the relative importance and prioritization of RWE being used for policy-making. A list of national-level databases and other sources of RWD available in each country was compiled. A list of useful guidance on data collection, quality assurance and study design were also compiled., Conclusion: The REALISE guidance document serves to align the collection of better quality RWD and generation of reliable RWE to ultimately inform HTA in Asia., (© 2023 The Author(s); Published by Kerman University of Medical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.)

There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.